Peer Reviewed Orthopaedic Integrated Clinical Trial Award

The summary for the Peer Reviewed Orthopaedic Integrated Clinical Trial Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
Peer Reviewed Orthopaedic Integrated Clinical Trial Award: The PRORP is offering the Integrated Clinical Trial Award (ICTA) for the first time in FY16. The PRORP ICTA supports the rapid implementation of an interdisciplinary clinical trial that integrates both surgical and rehabilitation strategies and has the potential to have a major impact on both the treatment of combat-related orthopaedic injuries, as well as the treatment of non-battle injuries that significantly impact unit readiness and return-to-duty/work rates. Projects that follow patients across the continuum of care are highly encouraged. The projects should include both surgical and rehabilitation strategies that create a cohesive project. Surgical strategies are reconstruction and repair and/or application of biologics, pharmaceuticals, and devices for the purpose of restoration of native architecture, composition, and function of traumatically injured tissues. Rehabilitative strategies are those that restore function following injury or illness, with the goal of optimal health and independence. Projects should integrate principles and approaches from surgical and rehabilitative strategies, beyond what each approach would result in alone, with the goal of optimizing form, function, and independence for those who have sustained traumatic orthopaedic injuries. Care should be taken to avoid or account for confounding factors in the analyses.All applications are required to articulate the relevance of the proposed interdisciplinary project to military and/or Veteran populations affected by orthopaedic injury. Collaboration with military and Department of Veteran Affairs (VA) researchers and /or clinicians is encouraged. Studies that include active duty military or Veteran participants as all or a portion of the study population are encouraged. All funding amounts requested should be well-justified and appropriate to the scope of work proposed. Funding from this award mechanism must support one cohesive clinical trial and may not be used for preclinical research studies. Animal research is not allowed under the FY16 PRORP ICTA. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other award mechanisms/funding opportunities being offered. The term “human subjects” is used in this Program Announcement/Funding Opportunity to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm. If the clinical trial involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, then an Investigational New Drug (IND) application to the FDA that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) may be required and must be submitted to the FDA within 6 months of the award date. If the investigational product is a device, evidence that an Investigational Device Exemption (IDE) application that meets all requirements under 21 CFR 812 has been submitted to the FDA within 6 months of the award date, or that the device is exempt from an IDE or qualifies for an abbreviated IDE, is required. The Government reserves the right to withdraw funding if an IND or IDE is necessary but has not been submitted to the FDA within 6 months of the award date, or if documented status of the IND or IDE has not been obtained within 12 months of the award date.The following are important aspects of submission for the Integrated Clinical Trial Award:• The proposed clinical trial is expected to begin no later than 12 months after the award date, or 18 months for FDA-regulated studies.• The proposed intervention to be tested should offer significant potential impact for military personnel and Veterans with combat-related orthopaedic injuries or non-battle orthopaedic injuries that impact unit readiness and return-to-duty/work. • Inclusion of preliminary data relevant to the proposed clinical trial is required. • The proposed clinical trial must be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.• The application should describe the planned indication for the product label, if appropriate. Likewise, it should include an outline of the development plan and regulatory strategy required to support that indication.• The application should demonstrate availability of, and access to, a suitable patient population that will support a meaningful outcome for the study. The applicant should discuss how accrual goals will be achieved and how standards of care may impact the study enrollment.• The application should demonstrate documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate. The quality of the product should be commensurate with FDA manufacturing standards applicable to the type and phase of product being developed (i.e., Quality System Regulation, Good Manufacturing Practices).• The application should demonstrate the study team has experience interacting with the FDA, to include previous FDA submissions, if applicable.• The proposed clinical trial design should include clearly defined and appropriate endpoints, and follow Good Clinical Practice (GCP) guidelines. • The application should include a clearly articulated statistical analysis plan, appropriate statistical expertise on the research team, and a power analysis reflecting sample size projections that will clearly answer the objectives of the study.• The application should include a clearly articulated data management plan and use of an appropriate database to safeguard and maintain the integrity of the data. For FDA-regulated studies, compliance with 21 CFR 11 is required.• The application should include a clearly articulated safety management plan outlining how safety and pharmacovigilance will be conducted, as applicable.• The application should include a clearly articulated clinical monitoring plan outlining how the study will be monitored for GCP compliance.• The application should include a study coordinator(s) who will guide the clinical protocol through the local Institutional Review Board (IRB) of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual.• For studies determined to be greater than minimal risk to human subjects by the local IRB of record, the Department of Defense (DoD) requires an independent research monitor with expertise consistent with the nature of risk(s) identified within the research project. If applicable, refer to the General Application Instructions, Appendix 6, for more information on study reporting authorities and responsibilities of the research monitor.• The application should include a Transition Plan (including potential funding and resources) showing how the product will progress to the next clinical trial phase and/or delivery to the market after the successful completion of the FY16 PRORP ICTA.• The application should clearly demonstrate strong institutional support (refer to Section II.C., Full Application Submission Content, Supporting Documentation).• Funded studies are required to file the study in the National Institutes of Health clinical trials registry, www.clinicaltrials.gov. Refer to the General Application Instructions, Appendix 6, Section C, for further details.Multi-Institutional Clinical Trials: If the proposed clinical trial is multi-institutional, plans for communication and data transfer among the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the application. A separate intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials.Required Qualified Collaborator(s): The ICTA supports collaborative interdisciplinary research between/among physical therapists, occupational therapists, prosthetists, surgeons, and other orthopaedic care providers. To encourage meaningful and productive multidisciplinary collaborations, the project must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care. A clinician is defined as an individual who is credentialed (possesses the necessary degrees, licenses, and other certifications) and practicing as a care provider in a relevant capacity. Biographical sketches should include appropriate documentation of credentials. It is the responsibility of the PI and the collaborating investigators to describe how their combined expertise will better address the research question, why the work should be performed through collaboration rather than through separate efforts, and how the research design will create a reciprocal flow of ideas and information between the multiple disciplines represented. The proposed collaboration should involve substantial contributions from each of the key collaborators identified, with evidence of significant intellectual input from each key collaborator into the design of the project. The PI must submit a Qualified Collaborator Statement that clearly describes the proposed collaborator(s), the collaboration, and addresses how each of the criteria below are met. Use Attachment 9 (Study Personnel & Organization) to provide this statement (see Section II.C., Full Application Submission Content). In addition, each collaborator must provide a letter of collaboration describing his/her involvement in the proposed work. Use Attachment 2 to provide this documentation (see Section II.C., Full Application Submission Content, Supporting Documentation, Letters of Collaboration). The following criteria must be met for the required Qualified Collaborator(s):• A Qualified Collaborator must be an investigator with orthopaedic rehabilitation expertise or a clinician who specializes in orthopaedic or trauma care.• The Qualified Collaborator(s) must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement. This is expected to include both intellectual input and research resources (e.g., supplies, reagents, equipment, personnel, services, tissue samples, or access to patients or populations).• The Qualified Collaborator(s) and PI must each contribute a minimum of a 5% level of effort to the project. Contribution of the Qualified Collaborator(s) and PI should be reflected in the application budget.Encouraged DoD and VA Collaboration and Alignment: Military relevance is a key feature of this award. Therefore, PIs are strongly encouraged to collaborate, integrate, and/or align their projects with military and/or VA research laboratories and programs. Although not a comprehensive list, the following websites may be useful in identifying information about DoD and VA areas of research interest, ongoing research, or potential opportunities for collaboration: Air Force Office of Scientific Researchhttp://www.wpafb.af.mil/afrl/afosr/Air Force Research Laboratory http://www.wpafb.af.mil/afrl Armed Forces Radiobiology Research Institute http://www.usuhs.edu/afrri/ Clinical and Rehabilitative Medicine Research Program https://crmrp.amedd.army.milCombat Casualty Care Research Program https://ccc.amedd.army.mil Congressionally Directed Medical Research Programs http://cdmrp.army.milDefense Advanced Research Projects Agency http://www.darpa.mil/ Defense Technical Information Center http://www.dtic.milDefense Threat Reduction Agencyhttp://www.dtra.mil/Military Health System Research Symposiumhttps://mhsrs.amedd.army.mil/SitePages/Home.aspxMilitary Infectious Diseases Research Program https://midrp.amedd.army.milMilitary Operational Medicine Research Program https://momrp.amedd.army.mil Naval Health Research Center http://www.med.navy.mil/sites/nhrcNavy and Marine Corps Public Health Center http://www.nmcphc.med.navy.mil/Office of Naval Research http://www.med.navy.mil/Office of the Under Secretary of Defense for Acquisition, Technology and Logistics http://www.acq.osd.mil/Telemedicine and Advanced Technology Research Centerhttp://www.tatrc.org/Uniformed Services University of the Health Sciences http://www.usuhs.edu/researchU.S. Army Institute of Surgical Researchhttp://www.usaisr.amedd.army.mil/ U.S. Army Research Institute of Environmental Medicinehttp://www.usariem.army.mil/U.S. Army Medical Research Institute of Infectious Diseaseshttp://www.usamriid.army.mil/U.S. Army Medical Research and Materiel Command https://mrmc.amedd.army.milU.S. Army Research Laboratory http://www.arl.army.milU.S. Department of Defense Blast Injury Research Program https://blastinjuryresearch.amedd.army.mil/U.S. Department of Veterans Affairs, Office of Research and Development http://www.research.va.govU.S. Naval Research Laboratory http://www.nrl.navy.milWalter Reed Army Institute of Research http://wrair-www.army.mil Use of Military and VA Populations or Resources: If the proposed research plan involves access to active duty military and/or VA patient populations or resources, the PI is responsible for establishing such access. If possible, access to target active duty military and/or VA patient populations/resources should be confirmed at the time of application submission by inclusion of a letter of support, signed by the lowest ranking person with approval authority, for studies involving active duty military Service members, Veterans, military- and/or VA-controlled study materials, and military and/or VA databases. If access cannot be confirmed at the time of application submission, the Government reserves the right to withhold or revoke funding until the PI has demonstrated support for and access to the relevant population(s) and/or resources. Note that access to a Veteran population for clinical studies may only be obtained by either collaboration with a VA investigator, where the VA investigator has a substantial role in the research, or by advertising to the general public. Use Attachment 2 to provide this documentation (see Section II.C., Full Application Submission Content, Supporting Documentation).Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DoD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO) prior to research implementation. This administrative review requirement is in addition to the local IRB or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. The HRPO is mandated to comply with specific laws and requirements governing all research involving human anatomical substances, human subjects, or human cadavers that is supported by the DoD. These laws and requirements will necessitate information in addition to that supplied to the IRB/EC. Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes. Refer to the General Application Instructions, Appendix 6, and the Human Subject Resource Document available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information. If the IRB determines that a trial presents greater than minimal risk to human subjects, the DoD requires an independent research monitor with expertise consistent with the nature of risk(s) identified within the research protocol. If applicable, please refer to the General Application Instructions, Appendix 6, for more information on study reporting authorities and responsibilities of the research monitor.The CDMRP intends that information, data, and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 4, Section K.
Federal Grant Title: Peer Reviewed Orthopaedic Integrated Clinical Trial Award
Federal Agency Name: Dept of the Army USAMRAA (DOD-AMRAA)
Grant Categories: Science and Technology
Type of Opportunity: Discretionary
Funding Opportunity Number: W81XWH-16-PRORP-ICTA
Type of Funding: Cooperative Agreement
CFDA Numbers: 12.420
CFDA Descriptions: Information not provided
Current Application Deadline: December 7th, 2016
Original Application Deadline: December 7th, 2016
Posted Date: August 10th, 2016
Creation Date: August 10th, 2016
Archive Date: January 6th, 2017
Total Program Funding: $30,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards: 1
Cost Sharing or Matching: No
Last Updated: August 10th, 2016
Applicants Eligible for this Grant
Unrestricted (i.e., open to any type of entity below), subject to any clarification in text field entitled "Additional Information on Eligibility"
Grant Announcement Contact
CDMRP Help Desk
Phone: 301-682-5507
Email: [email protected]

CDMRP Help Desk
Similar Government Grants
DoD Peer Reviewed Medical, Impact Award
DoD Peer Reviewed Medical, Lifestyle and Behavioral Health Interventions Research Award
DoD Peer Reviewed Medical, Discovery Award
DoD Peer Reviewed Medical, Technology/Therapeutic Development Award
DoD Peer Reviewed Medical, Clinical Trial Award
FY2006 Deployed War Fighter Protection Research Program
Department of Defense (DOD) Fiscal Year 2003 (FY03) Breast Cancer Research Program (BCRP)C...
Department of Defense (DOD) Fiscal Year 2004 (FY04) Breast Cancer Research Program (BCRP) ...
More Grants from the Dept of the Army USAMRAA
Spinal Cord Injury Research Program Clinical Translation Research Award
Spinal Cord Injury Research Program Clinical Trial Award
DoD Hearing Restoration Focused Research Award
DOD Spinal Cord Injury Research Program Translational Research Award
DoD Autism, Clinical Trial Award

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com